Apellis’s pegcetacoplan – approved for two other indications – will not go forward in amyotrophic lateral sclerosis after a Phase II failure, two days after Wave Life made a similar call in the neurodegenerative disease.

Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.

Investment bank analysts, VC funds and biopharma companies all sought to calm investors’ nerves as a go-to financial institution for tech and biotech collapsed.

Start-up hopes to bring its first candidate, an NY-ESO-1-targeting off-the-shelf product, into the clinic in Q2. Astex and Cardiff University team up on novel therapies for neurodegenerative disease.